Your browser doesn't support javascript.
loading
Pharmacoeconomic implications of preference toward reference- versus generic-brand antidepressants in primary care.
Gultekin, Onur; Aydin, Volkan; Bayram, Dilara; Atac, Omer; Akici, Ahmet.
Afiliação
  • Gultekin O; Department of Medical Pharmacology, School of Medicine, Marmara University, Istanbul, Turkey.
  • Aydin V; Department of Medical Pharmacology, International School of Medicine, Istanbul Medipol University, Istanbul, Turkey.
  • Bayram D; Department of Pharmacology, School of Pharmacy, Acibadem Mehmet Ali Aydinlar University, Istanbul, Turkey.
  • Atac O; Department of Public Health, International School of Medicine, Istanbul Medipol University, Istanbul, Turkey.
  • Akici A; Department of Health Management and Policy, College of Public Health, University of Kentucky, Lexington, KY, USA.
Prim Health Care Res Dev ; 25: e40, 2024 Sep 20.
Article em En | MEDLINE | ID: mdl-39301599
ABSTRACT

BACKGROUND:

The prevalence of depression is gradually increasing worldwide with an increasing utilization of antidepressants. Nevertheless, despite their lower costs, generic-brand antidepressants were reported to be less prescribed. We aimed to examine the costs of reference- versus generic-brand antidepressant prescriptions in primary care practice.

METHODS:

This cross-sectional study included electronic prescriptions for adult patients that contained antidepressants (World Health Organization's Anatomical Therapeutic Chemical (ATC) code N06A), which were generated by a systematically selected sample of primary care doctors (n = 1431) in Istanbul in 2016. We examined the drug groups preferred, the reference- versus generic-brand status, and pharmacotherapy costs.

FINDINGS:

The majority of the prescriptions were prescribed for women (71.8%), and the average age of the patients was 53.6 ± 16.2 years. In prescriptions with a depression-related indication (n = 40 497), the mean number and cost of drugs were 1.5 ± 1.0 and 22.7 ± 26.4 United States Dollar ($) per prescription, respectively. In these prescriptions, the mean number and cost of antidepressants per encounter were 1.1 ± 0.2 and $17.0 ± 13.2, respectively. Reference-brand antidepressants were preferred in 58.2% of depression-related prescriptions, where the mean cost per prescription was $18.3 ± 12.4. The mean cost per prescription of the generics, which constituted 41.8% of the antidepressants in prescriptions, was $15.1 ± 11.4. We found that if the generic version with the lowest cost was prescribed instead of the reference-brand, the mean cost per prescription would be $12.9 ± 11.2.

CONCLUSIONS:

Our study highlighted the substantial pharmacoeconomic impact of generic-brand antidepressant prescribing, whose preference over reference-brands could reduce the cost of antidepressant medication treatment by 17.5% in primary care, which could be approximately doubled if the cheapest generic antidepressant had been prescribed.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Atenção Primária à Saúde / Medicamentos Genéricos / Antidepressivos Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Prim Health Care Res Dev Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Turquia País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Atenção Primária à Saúde / Medicamentos Genéricos / Antidepressivos Limite: Adult / Aged / Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Revista: Prim Health Care Res Dev Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Turquia País de publicação: Reino Unido